| 47244-9 |
Symptom, diagnosis, or opportunistic infection related to HIV Rx |
Type |
^Patient |
Pt |
Nom |
Reported |
|
ACTIVE |
Symptom, diagnosis, or opportunistic infection related to HIV treatment |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47244-9 |
|
Reported |
|
|
Observation |
|
|
|
0 |
Symptom, Dx, or infect related to HIV Rx |
|
|
|
N |
|
AIDS; Anti-retroviral therapy; ART; Dx; Human immunodeficiency virus; ID; Infectious Disease; InfectiousDisease; Nominal; Point in time; Random; Sx; Symptom, Dx, or infect related to HIV Rx; Treatment; Typ |
2.67 |
2.22 |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 47245-6 |
HIV Rx Form |
- |
Form |
Pt |
Doc |
|
|
ACTIVE |
HIV treatment form Document |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
PANEL.ART |
|
47245-6 |
|
|
|
|
Order |
|
|
|
0 |
HIV Rx Form Doc |
|
|
|
N |
|
AIDS; Anti-retroviral therapy; ART; Document; Human immunodeficiency virus; Pan; Panel; PANEL.ANTIRETROVIRAL THERAPY; Panl; Pnl; Point in time; Random; Treatment |
2.67 |
2.22 |
|
Panel |
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 47246-4 |
Demographic information section |
- |
^Patient |
Pt |
Set |
HIV-ART |
|
ACTIVE |
HIV Antiretroviral therapy Demographic information section |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47246-4 |
|
HIV-ART |
|
|
Order |
|
|
|
0 |
Demographic information section |
|
|
|
N |
|
ID; Infectious Disease; InfectiousDisease; Point in time; Random |
2.67 |
2.22 |
|
Panel |
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 47247-2 |
Outpatient encounter-level information section |
- |
^Patient |
Pt |
Set |
HIV-ART |
|
ACTIVE |
HIV Antiretroviral therapy Outpatient encounter-level information section |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47247-2 |
|
HIV-ART |
|
|
Observation |
|
|
|
0 |
OP encounter-level info section |
|
|
|
N |
|
ID; Infectious Disease; InfectiousDisease; Levels; Levl; LV; LVL; OP; OP encounter-level info section; Point in time; Random |
2.67 |
2.22 |
|
Panel |
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 47248-0 |
Antiretroviral therapy status section |
- |
^Patient |
Pt |
Set |
HIV-ART |
|
ACTIVE |
HIV Antiretroviral therapy Antiretroviral therapy status section |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47248-0 |
|
HIV-ART |
|
|
Order |
|
|
|
0 |
Antiretroviral therapy status section |
|
|
|
N |
|
ID; Infectious Disease; InfectiousDisease; Point in time; Random |
2.67 |
2.22 |
|
Panel |
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 47249-8 |
HIV care & family status section |
- |
^Patient |
Pt |
Set |
HIV-ART |
|
ACTIVE |
HIV Antiretroviral therapy HIV care and family status section |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47249-8 |
|
HIV-ART |
|
|
Order |
|
|
|
0 |
HIV care & family status section |
|
|
|
N |
|
AIDS; Human immunodeficiency virus; ID; Infectious Disease; InfectiousDisease; Point in time; Random |
2.67 |
2.22 |
|
Panel |
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 4725-8 |
HLA-A26(10) |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-A26(10) [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4725-8 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A26(10) Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47250-6 |
Adenosine monophosphate.cyclic^2nd specimen post XXX challenge |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Adenosine monophosphate.cyclic [Moles/volume] in Urine --2nd specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
umol/L |
1.8 umol/L |
|
|
|
|
|
CHAL |
|
47250-6 |
|
|
|
|
Observation |
|
|
|
0 |
cAMP sp2 p chal Ur-sCnc |
|
|
|
N |
|
Adenosine 2'-Phosphate; Adenosine 3'-Phosphate; Adenosine 5'-Phosphate; Adenylic Acid; ADO; After; AMP; ANED; cAMP; CHEMISTRY.CHALLENGE TESTING; CMP; Convalescent; Level; Medication stress; p chal; Phosphaden; Point in time; Post immunization; PST; QNT; Quan; Quant; Quantitative; Random; Second; sp2; sp2 p chal; Spec; Substance concentration; UA; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 47251-4 |
BK virus DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
BK virus DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
No BK virus DNA detected. or BK virus DNA detected. |
|
|
|
|
|
MICRO |
|
47251-4 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
BKV DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; BKV; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47252-2 |
Hepatitis C virus RNA |
LnCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Hepatitis C virus RNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
log copies/mL |
|
|
|
|
|
|
MICRO |
|
47252-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HCV RNA SerPl NAA+probe-Log# |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; HCV; Hep; Hep C; Hepatis; Hepatit; Hepatology; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Liver; Log NCNC; Log#; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; UniversalLabOrders; Viral load |
2.73 |
2.19 |
|
|
|
|
|
|
|
{log_copies}/mL |
|
|
|
0 |
| 47253-0 |
Coproporphyrin 1 |
MCnc |
Urine |
24H |
Qn |
|
|
ACTIVE |
Coproporphyrin 1 [Mass/volume] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
15 ug/L |
|
|
|
|
|
CHEM |
|
47253-0 |
|
|
|
|
Both |
|
|
|
0 |
Copro1 24h Ur-mCnc |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Copro; Copro1; Coproporph; Coproporphyrin I; Coproporphyrins; Hematology; Heme; i; Level; Mass concentration; QNT; Quan; Quant; Quantitative; Tetracarboxyl porphyrin; Tetracarboxylporphyrin; Tetracarboxylporphyrins; Tetracarboxyporphyrin; UA; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 47254-8 |
Coproporphyrin 3 |
MCnc |
Urine |
24H |
Qn |
|
|
ACTIVE |
Coproporphyrin 3 [Mass/volume] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ug/L |
|
|
|
|
|
CHEM |
|
47254-8 |
|
|
|
|
Both |
|
|
|
0 |
Copro3 24h Ur-mCnc |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Copro; Copro3; Coproporph; Coproporphyrin III; Coproporphyrins; Hematology; Heme; III; Level; Mass concentration; QNT; Quan; Quant; Quantitative; Tetracarboxyl porphyrin; Tetracarboxylporphyrin; Tetracarboxylporphyrins; Tetracarboxyporphyrin; UA; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 47255-5 |
Procollagen type I.N-terminal propeptide |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Procollagen type I.N-terminal propeptide [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
ug/L |
55 ug/L |
|
|
|
|
|
CHEM |
|
47255-5 |
|
|
|
|
Both |
|
|
|
0 |
PINP Ser-mCnc |
|
|
|
N |
|
Chemistry; Level; Mass concentration; P1NP; PINP; Point in time; Procollagen I; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 47256-3 |
Creatinine^2nd specimen post XXX challenge |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Urine --2nd specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
g/L; mcg/mL; mg/dL; mg/mL |
15.0 mg/dL |
|
|
|
|
|
CHAL |
|
47256-3 |
|
|
|
|
Observation |
|
|
|
0 |
Creat sp2 p chal Ur-mCnc |
|
|
|
N |
|
After; CHEMISTRY.CHALLENGE TESTING; Convalescent; CR; Crea; Creat; Level; Mass concentration; p chal; Point in time; Post immunization; PST; QNT; Quan; Quant; Quantitative; Random; Second; sp2; sp2 p chal; Spec; UA; UCr; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 47257-1 |
Creatinine^1st specimen post XXX challenge |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Urine --1st specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
g/L; mcg/mL; mg/dL; mg/mL |
15.0 mg/dL |
|
|
|
|
|
CHAL |
|
47257-1 |
|
|
|
|
Observation |
|
|
|
0 |
Creat sp1 p chal Ur-mCnc |
|
|
|
N |
|
Acute specimen; After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; First; Level; Mass concentration; p chal; Point in time; Pre immunization; PST; QNT; Quan; Quant; Quantitative; Random; sp1; sp1 p chal; Spec; UA; UCr; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 47258-9 |
Creatinine^3rd specimen post XXX challenge |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Urine --3rd specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
g/L; mcg/mL; mg/dL; mg/mL |
16.5 mg/dL |
|
|
|
|
|
CHAL |
|
47258-9 |
|
|
|
|
Observation |
|
|
|
0 |
Creat sp3 p chal Ur-mCnc |
|
|
|
N |
|
After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; sp3; sp3 p chal; Spec; UA; UCr; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 47259-7 |
Creatinine^4th specimen post XXX challenge |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Urine --4th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
g/L; mcg/mL; mg/dL; mg/mL |
16.5 mg/dL |
|
|
|
|
|
CHAL |
|
47259-7 |
|
|
|
|
Observation |
|
|
|
0 |
Creat sp4 p chal Ur-mCnc |
|
|
|
N |
|
After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; sp4; sp4 p chal; Spec; UA; UCr; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 4726-6 |
HLA-A28 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A28 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4726-6 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A28 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47260-5 |
Plasmodium sp DNA |
Prid |
Bld |
Pt |
Nom |
Probe.amp.tar |
|
ACTIVE |
Plasmodium sp DNA [Identifier] in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
Plasmodium malariae DNA detected. Plasmodium falciparum DNA detected. Plasmodium ovale DNA detected. Plasmodium vivax DNA detected. No plasmodium species DNA detected. |
|
|
|
|
|
MICRO |
|
47260-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Plasmodium DNA Bld NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Identity or presence; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Malaria; Malarial; Microbiology; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; PCR; Plasmodium DNA; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; species; spp; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 47261-3 |
Creatinine^6th specimen post XXX challenge |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Creatinine [Mass/volume] in Urine --6th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
g/L; mcg/mL; mg/dL; mg/mL |
15.0 mg/dL |
|
|
|
|
|
CHAL |
|
47261-3 |
|
|
|
|
Observation |
|
|
|
0 |
Creat sp6 p chal Ur-mCnc |
|
|
|
N |
|
After; CHEMISTRY.CHALLENGE TESTING; CR; Crea; Creat; Level; Mass concentration; p chal; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; sp6; sp6 p chal; Spec; UA; UCr; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 47262-1 |
Adenosine monophosphate.cyclic^6th specimen post XXX challenge |
Ratio |
Urine |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --6th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
nmol/mg creatinine |
|
|
|
|
|
|
CHAL |
|
47262-1 |
|
|
|
|
Observation |
|
|
|
0 |
Deprecated cAMP sp6 p chal Ur-Rto |
|
|
|
N |
|
Adenosine 2'-Phosphate; Adenosine 3'-Phosphate; Adenosine 5'-Phosphate; Adenylic Acid; ADO; After; AMP; ANED; cAMP; CHEMISTRY.CHALLENGE TESTING; CMP; Medication stress; p chal; Phosphaden; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto; sp6; sp6 p chal; Spec; UA; UR; Urn |
2.7 |
2.19 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 47263-9 |
Adenosine monophosphate.cyclic^3rd specimen post XXX challenge |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Adenosine monophosphate.cyclic [Moles/volume] in Urine --3rd specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHAL |
|
47263-9 |
|
|
|
|
Observation |
|
|
|
0 |
cAMP sp3 p chal Ur-sCnc |
|
|
|
N |
|
Adenosine 2'-Phosphate; Adenosine 3'-Phosphate; Adenosine 5'-Phosphate; Adenylic Acid; ADO; After; AMP; ANED; cAMP; CHEMISTRY.CHALLENGE TESTING; CMP; Level; Medication stress; p chal; Phosphaden; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; sp3; sp3 p chal; Spec; Substance concentration; UA; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 47264-7 |
Adenosine monophosphate.cyclic^1st specimen post XXX challenge |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Adenosine monophosphate.cyclic [Moles/volume] in Urine --1st specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHAL |
|
47264-7 |
|
|
|
|
Observation |
|
|
|
0 |
cAMP sp1 p chal Ur-sCnc |
|
|
|
N |
|
Acute specimen; Adenosine 2'-Phosphate; Adenosine 3'-Phosphate; Adenosine 5'-Phosphate; Adenylic Acid; ADO; After; AMP; ANED; cAMP; CHEMISTRY.CHALLENGE TESTING; CMP; First; Level; Medication stress; p chal; Phosphaden; Point in time; Pre immunization; PST; QNT; Quan; Quant; Quantitative; Random; sp1; sp1 p chal; Spec; Substance concentration; UA; UR; Urn |
2.73 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 47265-4 |
Adenosine monophosphate.cyclic^4th specimen post XXX challenge |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Adenosine monophosphate.cyclic [Moles/volume] in Urine --4th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHAL |
|
47265-4 |
|
|
|
|
Observation |
|
|
|
0 |
cAMP sp4 p chal Ur-sCnc |
|
|
|
N |
|
Adenosine 2'-Phosphate; Adenosine 3'-Phosphate; Adenosine 5'-Phosphate; Adenylic Acid; ADO; After; AMP; ANED; cAMP; CHEMISTRY.CHALLENGE TESTING; CMP; Level; Medication stress; p chal; Phosphaden; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; sp4; sp4 p chal; Spec; Substance concentration; UA; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 47266-2 |
Adenosine monophosphate.cyclic^5th specimen post XXX challenge |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Adenosine monophosphate.cyclic [Moles/volume] in Urine --5th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHAL |
|
47266-2 |
|
|
|
|
Observation |
|
|
|
0 |
cAMP sp5 p chal Ur-sCnc |
|
|
|
N |
|
Adenosine 2'-Phosphate; Adenosine 3'-Phosphate; Adenosine 5'-Phosphate; Adenylic Acid; ADO; After; AMP; ANED; cAMP; CHEMISTRY.CHALLENGE TESTING; CMP; Level; Medication stress; p chal; Phosphaden; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; sp5; sp5 p chal; Spec; Substance concentration; UA; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
